益普索：2026年中国生物医药创新生态重塑全球肿瘤交易的未来研究报告：从星火到燎原（英文版）

The global pharmaceutical landscape is experiencing a fundamental shift as Chinese biopharmaceutical companies evolve from "fast followers" to innovation leaders, particularly in oncology. While several collaborations between Chinese biotechs and multinational corporations preceded it, the 2017 partnership between Legend Biotech and Johnson & Johnson (J&J) for their anti-BCMA chimeric antigen receptor T-cell (CAR-T) therapy Carvykti (ciltacabtagene autoleucel) represented a